A5090796568- Protein Degradation and Inhibitors
- Psychedelics and Drug Studies
- Chemistry and Chemical Engineering
- History and advancements in chemistry
- Ubiquitin and proteasome pathways
- Chemical synthesis and alkaloids
- Peptidase Inhibition and Analysis
- Neurotransmitter Receptor Influence on Behavior
- Biochemical and Molecular Research
- Multiple Myeloma Research and Treatments
- Tryptophan and brain disorders
- Protein Kinase Regulation and GTPase Signaling
- Advanced Breast Cancer Therapies
- Asymmetric Synthesis and Catalysis
- Histone Deacetylase Inhibitors Research
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Innovative Microfluidic and Catalytic Techniques Innovation
- Alkaloids: synthesis and pharmacology
- Prostate Cancer Treatment and Research
- Chronic Lymphocytic Leukemia Research
- Nicotinic Acetylcholine Receptors Study
- Melanoma and MAPK Pathways
- Microtubule and mitosis dynamics
- Treatment of Major Depression
Usona Institute
2017-2025
Albany Molecular Research (United States)
2013-2017
Albany Research Institute
2012-2013
North Dakota State University
2004-2010
University of Bristol
2007
Bay College
2004
The asymmetric hydrogenation of tetrasubstituted olefins provides direct access to very useful biological molecules and intermediates. development the technology has been slow, due in part synthetic challenges involved developing chiral catalysts for a successful induction. We briefly recount breakthroughs functionalized unfunctionalized olefins, from reports Zhou Buchwald substrates, respectively, advent phosphoramidite ligands. main emphasis this Perspective lies bringing into focus...
Thia−Fries rearrangement of BINOL perfluoroalkylsulfonates affords readily derivatized novel mono- and disulfone ligands in just two steps from enantiomerically pure BINOL. These electron-demanding BINOLs have been successfully applied as catalysts for indium-mediated allylation N-acylhydrazones. A general highly enantioselective catalytic process is described, which the presence perfluoroalkylsulfone (SO2RF) groups shown to be crucial activity selectivity. The corresponding homoallylic...
ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTPROTAC Compounds Targeting α-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer’s and Parkinson’s DiseasesRobert B. Kargbo*Robert KargboUsona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States*Email: [email protected]More by Robert Kargbohttp://orcid.org/0000-0002-5539-6343Cite this: ACS Med. Chem. Lett. 2020, 11, 6, 1086–1087Publication Date (Web):April 28, 2020Publication History...
A general synthetic method was developed to access known tryptamine natural products present in psilocybin-producing mushrooms. In vitro and vivo experiments were then conducted inform speculations on the psychoactive properties, or lack thereof, of products. animal models, psychedelic activity by baeocystin alone not evident using mouse head twitch response assay, despite its putative dephosphorylated metabolite, norpsilocin, possessing potent agonist at 5-HT2A receptor.
Since the discovery that indium could affect a Barbier-type allylation of carbonyls in water over decade ago, interest utility metal and its salts to influence organic transformations has increased exponentially. Control chemo-, regio-, especially stereoselectivity indium-mediated reactions proven be challenge, however, examples such discerning processes are now beginning appear on regular basis. Indium been found effective carbonyls, carbometallation some alkenes alkynes. It also shown...
Psilocybin, an active component in "magic mushroom", may have the potential to meet therapeutic needs for a number of indications without addictiveness and overdose risk other mind-altering drugs, such as cocaine, heroin, alcohol, methamphetamine, so forth. The need new therapies is urgent because addiction, overdose, suicide deaths risen throughout United States around world. Anecdotal contemporary pharmacological reports provided some indication about use psilocybin treatment mental health...
Abstract Psilocybin, the principal indole alkaloid of Psilocybe mushrooms, is currently undergoing clinical trials as a medication against treatment‐resistant depression and major depressive disorder. The psilocybin supply for pharmaceutical purposes met by synthetic chemistry. We replaced problematic phosphorylation step during synthesis with mushroom kinase PsiK. This enzyme was biochemically characterized used to produce one gram from psilocin within 20 minutes. also describe pilot‐scale...